Drug Profile
Nitric oxide synthase gene therapy - Cardion/Valentis
Alternative Names: iNOS gene therapy - Cardion/Valentis; NOStentinLatest Information Update: 16 Oct 2006
Price :
$50
*
At a glance
- Originator Cardion; Valentis
- Class Cell therapies; Gene therapies
- Mechanism of Action Nitric oxide synthase stimulants; Nitric oxide synthase type II modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Vascular restenosis
Most Recent Events
- 08 May 2001 Phase-I clinical trials for Vascular restenosis in USA (Unknown route)
- 27 Nov 2000 Cardiogene has merged with Intracardia to form Cardion
- 25 Jan 2000 Preclinical development for Vascular restenosis in Germany (Unknown route)